$ 5,943.20
Details
The Human Vascular Endothelial Growth Factor Receptor 2/KDR (Hu VEGFR2) ELISA quantitates Hu VEGFR2 in human serum, plasma, buffered solution, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu VEGFR2. Principle of the method The Human VEGFR2 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. VEGF are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGF Receptor 1 and VEGF Receptor 2 are both expressed in an endothelial cell-specific manner. They are detectable in virtually all tissues in adults and embryos. Monocytes express VEGF Receptor 1 and VEGF Receptor 2. VEGF Receptor 2 is involved in commitment of endothelial-cell lineages and to cell proliferation, while VEGF Receptor 1 seems to be responsible for guiding endothelial cells into the proper spatial organization of the lumen-containing vessels. VEGF Receptor 2 binds VEGF with high affinity but does not bind PIGF. The signalling and trafficking of this VEGF receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, and T-cell protein tyrosine phosphatase. Mutations of VEGF are implicated in infantile capillary hemangiomas.
